Sandoz Will Not Pursue US Advair Rival

Discontinuing Development Leads To $442m Impairment

Sandoz has decided to discontinue development of its generic version of GlaxoSmithKline’s Advair Diskus respiratory brand, resulting in an impairment charge of $442m.

Sportsman_Tired
Sandoz has given up on the race for a generic version of Advair Diskus • Source: Shutterstock

Sandoz has announced that it will no longer pursue a generic rival to GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) asthma treatment for the US market.

Announcing that it had discontinued its development program for generic Advair, Sandoz referred to a US Food and Drug Administration complete response letter received by the firm in 2018

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By 

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By 

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By 

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.